EA200800548A1 - HYBRID POLYPEPTIDES WITH SELECTED PROPERTIES - Google Patents

HYBRID POLYPEPTIDES WITH SELECTED PROPERTIES

Info

Publication number
EA200800548A1
EA200800548A1 EA200800548A EA200800548A EA200800548A1 EA 200800548 A1 EA200800548 A1 EA 200800548A1 EA 200800548 A EA200800548 A EA 200800548A EA 200800548 A EA200800548 A EA 200800548A EA 200800548 A1 EA200800548 A1 EA 200800548A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
type
hybrid polypeptides
disorders
insulin
Prior art date
Application number
EA200800548A
Other languages
Russian (ru)
Other versions
EA014647B1 (en
Inventor
Одиль Эстер Леви
Майкл Р. Ханли
Кэролин М. Джодка
Диана Льюис
Кристофер Дж. Соарес
Соумитра С. Гхош
Лоуренс Д'соуза
Дэвид Г. Паркес
Кристин М. Мэк
Бехроуз Брюс Форуд
Original Assignee
Амилин Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/206,903 external-priority patent/US8076288B2/en
Priority claimed from US11/301,744 external-priority patent/US7723471B2/en
Application filed by Амилин Фармасьютикалз, Инк. filed Critical Амилин Фармасьютикалз, Инк.
Priority claimed from PCT/US2006/031724 external-priority patent/WO2007022123A2/en
Publication of EA200800548A1 publication Critical patent/EA200800548A1/en
Publication of EA014647B1 publication Critical patent/EA014647B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Abstract

Данное изобретение главным образом относится к новым, селектируемым гибридным полипептидам, пригодным в качестве агентов для лечения и профилактики заболеваний и нарушений обмена веществ, которые могут быть облегчены контролем уровней глюкозы плазмы, уровней инсулина и/или секреции инсулина, таких как диабет и связанные с диабетом состояния. Такие состояния и нарушения включают, но не ограничены ими, гипертонию, дислипидемию, сердечно-сосудистое заболевание, нарушения питания, резистентность к инсулину, ожирение и сахарный диабет любого типа, включая тип 1, тип 2 и диабет при беременности.This invention mainly relates to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of diseases and metabolic disorders, which can be facilitated by the control of plasma glucose levels, insulin levels and / or insulin secretion, such as diabetes and associated with diabetes states. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, nutritional disorders, insulin resistance, obesity, and diabetes mellitus of any type, including type 1, type 2, and pregnancy diabetes.

EA200800548A 2005-08-11 2006-08-11 Hybrid polypeptides with selectable properties EA014647B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20166405A 2005-08-11 2005-08-11
US11/206,903 US8076288B2 (en) 2004-02-11 2005-08-17 Hybrid polypeptides having glucose lowering activity
US11/301,744 US7723471B2 (en) 2004-02-11 2005-12-12 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
PCT/US2006/031724 WO2007022123A2 (en) 2005-08-11 2006-08-11 Hybrid polypeptides with selectable properties

Publications (2)

Publication Number Publication Date
EA200800548A1 true EA200800548A1 (en) 2008-08-29
EA014647B1 EA014647B1 (en) 2010-12-30

Family

ID=39662713

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800548A EA014647B1 (en) 2005-08-11 2006-08-11 Hybrid polypeptides with selectable properties

Country Status (7)

Country Link
JP (1) JP2009504681A (en)
KR (1) KR101399178B1 (en)
CN (1) CN101296942A (en)
EA (1) EA014647B1 (en)
IL (1) IL188937A0 (en)
MX (1) MX2008002028A (en)
ZA (1) ZA200801138B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2416797A4 (en) * 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc Amylin agonist compounds for estrogen-deficient mammals
AU2010321587A1 (en) * 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2563808B1 (en) * 2010-04-27 2016-12-07 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
RU2552221C2 (en) * 2010-07-15 2015-06-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Method of treating obesity and accompanying metabolic disorders and medication for treating obesity and accompanying metabolic disorders
JP2014521594A (en) * 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Long duration dual hormone conjugate
TWI617574B (en) * 2012-12-11 2018-03-11 梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
KR20170069997A (en) * 2014-08-11 2017-06-21 알바니 메디칼 칼리지 Myristoylated leptin-related peptides and uses thereof
KR101689803B1 (en) * 2015-11-17 2016-12-27 고려대학교 산학협력단 Composition for preventing or treating of diabetes or obesity containing Apelin-16
WO2017120220A1 (en) * 2016-01-04 2017-07-13 Adepthera Llc Peptide analogs
JP6889432B2 (en) * 2016-04-28 2021-06-18 学校法人甲南学園 Resin-fixed peptide
BR112019004203A2 (en) * 2016-09-02 2019-06-25 Univ Illinois construct, pharmaceutical composition, and methods for inhibiting angiogenesis and for treating a disease or disorder in an individual distinguished by excessive vascularization.
WO2019054460A1 (en) * 2017-09-13 2019-03-21 株式会社ジーンテクノサイエンス Anti-ramp2 antibody
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202014433A (en) * 2018-04-25 2020-04-16 比利時商健生藥品公司 Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
KR102116944B1 (en) * 2019-09-23 2020-05-29 주식회사 차메디텍 Novel peptide derivatives having melanin production inhibitory activity, pharmaceutically acceptable salts thereof, and composition for inhibiting melanin production comprising the same
CN117603364A (en) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 GLP-1/glucon/Y 2 Receptor triple agonists and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
AU718254B2 (en) * 1996-01-19 2000-04-13 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
JP2000505105A (en) 1996-11-13 2000-04-25 ユニヴァーシティ・オブ・シンシナティ Analogs of peptide YY and uses thereof
DK0954588T3 (en) * 1996-12-20 2007-05-14 Amgen Inc OB fusion protein compositions and methods
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20030036504A1 (en) * 2000-01-10 2003-02-20 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
MXPA03005036A (en) * 2000-12-07 2003-09-05 Lilly Co Eli Glp-1 fusion proteins.
ATE408414T1 (en) * 2001-07-31 2008-10-15 Us Gov Health & Human Serv GLP 1 EXENDIN 4 PEPTIDE ANALOGUES AND THEIR USES
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
EP1610811A4 (en) * 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc Prevention and treatment of cardiac arrhythmias
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004089279A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
CN103897066A (en) * 2004-02-11 2014-07-02 安米林药品有限责任公司 Hybrid polypeptides with selectable properties

Also Published As

Publication number Publication date
EA014647B1 (en) 2010-12-30
IL188937A0 (en) 2008-04-13
KR101399178B1 (en) 2014-06-18
KR20080045185A (en) 2008-05-22
JP2009504681A (en) 2009-02-05
CN101296942A (en) 2008-10-29
ZA200801138B (en) 2008-12-31
MX2008002028A (en) 2008-03-27

Similar Documents

Publication Publication Date Title
EA200800548A1 (en) HYBRID POLYPEPTIDES WITH SELECTED PROPERTIES
EA200701704A1 (en) ANALOGUES AND HYBRID POLYPEPTIDES OF GIP WITH ELECTABLE PROPERTIES
WO2007022123A3 (en) Hybrid polypeptides with selectable properties
WO2005077072A3 (en) Hybrid polypeptides with selectable properties
WO2008021560A3 (en) Dpp-iv resistant gip hybrid polypeptides with selectable properties
EP2330125A3 (en) Hybrid polypeptides with selectable properties
IL198922A0 (en) Chemical compounds and uses
BE2021C505I2 (en)
WO2007007173A3 (en) Human anti-madcam antibodies
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
EA200701471A1 (en) Substituted pyridinyl and pyrimidinyl derivatives, used as modulators of metabolic disease and treatment of disorders associated with it
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
ATE539748T1 (en) GLUCOKINASE ACTIVATORS
EA201101189A1 (en) SGLT-2 INHIBITOR, INTENDED FOR THE TREATMENT OF TYPE 1 DIABETES TYPE 1, TYPE 2 DIABETES MELLITUS DIABETES, DISTURBED GLUCOSE TYPE OR HYPERGLYCEMIA
WO2007109024A3 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
WO2008106429A3 (en) Methods and compositions for the treatment of heart failure and other disorders
EA200501132A1 (en) 1,2,3-triple substituted aryl and heteroaryl derivatives as modulators of metabolism and prophylaxis and treatment of disorders associated with it, such as diabetes and hyperglycemia
EA201300522A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
WO2008147556A3 (en) Melanocortin receptor ligands modified with hydantoin

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU